SGLT2 inhibitors achieve similar glycemic control compared to DPP4 inhibitors in hospitalised patients, without an increase in overall complications, mortality or the risk of hypoglycaemia. A retrospective observational study of the EMR at the Austin Hospital comprised more than 10,000 inpatients with type 2 diabetes aged ≥ 54 years who received at least one oral ...
Type 2 diabetes
SGLT2 inhibitors vs DPP4 inhibitors compared in inpatients
By Mardi Chapman
12 Oct 2021